LPAR1 and idiopathic pulmonary fibrosis: In comparison, the plasma unbound concentration of admilparant (BMS-986278), an LPAR1 antagonist being evaluated in Phase 3 for the treatment of IPF and progressive pulmonary fibrosis (PPF) at oral doses of 60 and 120 mg twice a day (BID), was only above its measured IC50 (80.4 nM ×/÷ 1.58, n = 6) for 4 h when dosed orally in rats at 10 mg/kg (Supp Fig S9).